[
  {
    "ts": null,
    "headline": "Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance",
    "summary": "SAN DIEGO, August 06, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance.",
    "url": "https://finnhub.io/api/news?id=6ba3dfd3d4c88a23bde28d918f51a840fc5837aff4e7636ba2e63c016ab4041d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754510700,
      "headline": "Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance",
      "id": 136246235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "SAN DIEGO, August 06, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance.",
      "url": "https://finnhub.io/api/news?id=6ba3dfd3d4c88a23bde28d918f51a840fc5837aff4e7636ba2e63c016ab4041d"
    }
  },
  {
    "ts": null,
    "headline": "Senseonics Holdings, Inc. Reports Second Quarter Financial Results",
    "summary": "Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent",
    "url": "https://finnhub.io/api/news?id=50b2ae7ff1a72422016eb5c6c6ff8fb6a16b90c8d9465f062add5d13cd687931",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754510700,
      "headline": "Senseonics Holdings, Inc. Reports Second Quarter Financial Results",
      "id": 136240879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent",
      "url": "https://finnhub.io/api/news?id=50b2ae7ff1a72422016eb5c6c6ff8fb6a16b90c8d9465f062add5d13cd687931"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=f58ec1f713d087fa1be0ea518497393fe813bcdea902cac051311bad4360e6f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754485202,
      "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136237240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=f58ec1f713d087fa1be0ea518497393fe813bcdea902cac051311bad4360e6f0"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?",
    "summary": "ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.",
    "url": "https://finnhub.io/api/news?id=942587638154c4d740e2ff9e56bc92d2b22cf7014f5e43b443b41fd4c6d9f5a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754480460,
      "headline": "Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?",
      "id": 136237241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.",
      "url": "https://finnhub.io/api/news?id=942587638154c4d740e2ff9e56bc92d2b22cf7014f5e43b443b41fd4c6d9f5a8"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories' (NYSE:ABT) Earnings Are Of Questionable Quality",
    "summary": "Investors were disappointed with Abbott Laboratories' ( NYSE:ABT ) earnings, despite the strong profit numbers. Our...",
    "url": "https://finnhub.io/api/news?id=8232d622a793b788c03e92bb8f3bdffb01223d2965061d9a85b6f816004b10ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754479767,
      "headline": "Abbott Laboratories' (NYSE:ABT) Earnings Are Of Questionable Quality",
      "id": 136232281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Investors were disappointed with Abbott Laboratories' ( NYSE:ABT ) earnings, despite the strong profit numbers. Our...",
      "url": "https://finnhub.io/api/news?id=8232d622a793b788c03e92bb8f3bdffb01223d2965061d9a85b6f816004b10ed"
    }
  },
  {
    "ts": null,
    "headline": "Auxier Asset Management Summer 2025 Market Commentary",
    "summary": "Markets have been a rollercoaster for investors in 2025, with every major benchmark starting the year down in the first quarter to all being up for the second quarter and year-to-date.",
    "url": "https://finnhub.io/api/news?id=eadda7b84c914659d8a4bacbbdaaa3f292348896b4f845a356bbe7409ff8c4a3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754455140,
      "headline": "Auxier Asset Management Summer 2025 Market Commentary",
      "id": 136231483,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215724553/image_2215724553.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Markets have been a rollercoaster for investors in 2025, with every major benchmark starting the year down in the first quarter to all being up for the second quarter and year-to-date.",
      "url": "https://finnhub.io/api/news?id=eadda7b84c914659d8a4bacbbdaaa3f292348896b4f845a356bbe7409ff8c4a3"
    }
  },
  {
    "ts": null,
    "headline": "Medical Devices & Supplies - Diversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT)",
    "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including Abbott Laboratories (NYSE:ABT) and its peers.",
    "url": "https://finnhub.io/api/news?id=f69d74a905ff587e1074b5a83b8ef1c8c61f35bc2cc07d4787c32fe4c44061f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754451157,
      "headline": "Medical Devices & Supplies - Diversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT)",
      "id": 136239035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including Abbott Laboratories (NYSE:ABT) and its peers.",
      "url": "https://finnhub.io/api/news?id=f69d74a905ff587e1074b5a83b8ef1c8c61f35bc2cc07d4787c32fe4c44061f1"
    }
  }
]